COVID-19 Could Change Attitudes To Flu, Bolster Xofluza
Roche's Xofluza Gains EU Approval
Roche’s first-in-class one-dose antiviral Xofluza has been approved for marketing in the EU to treat influenza in patients aged 12 years or over, and for post-exposure prophylaxis.
You may also be interested in...
This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the European Union, and updates on EU marketing authorization changes recommended by the CHMP.
Oncology partnership with Swiss major follows late 2020 pact with Merck KGaA. Pfizer divests Phase Ib breast cancer candidate to Celcuity.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.